PCA3 и TMPRSS2-ERG в диагностике РПЖ: первый опыт применения комбинации маркеров в России

PCA3 и TMPRSS2-ERG в диагностике РПЖ: первый опыт применения комбинации маркеров в России

Автор: Аполихин О.И., Сивков А.В., Ефремов Г.Д., Михайленко Д.С., Шадеркин И.А., Войтко Д.А., Просянников М.Ю., Григорьева М.В.

Журнал: Экспериментальная и клиническая урология @ecuro

Рубрика: Онкоурология

Статья в выпуске: 2, 2015 года.

Бесплатный доступ

За последние 20 лет предложено множество новых маркеров рака предстательной железы (РПЖ), среди них - комбинация PCA3 и TMPRSS2-ERG. В НИИ урологии разрабатывается методика совместного определения экспрессии PCA3 и TMPRSS2-ERG в моче и ткани предстательной железы (ПЖ), основанная на ПЦР с обратной транскрипцией в реальном времени. Для оценки диагностической значимости разрабатываемой методики, проанализированы две независимые выборки, представленные образцами ткани ПЖ (n=78) и мочи (n=56). Оценивали уровень сывороточного PSA, патоморфологические результаты, экспрессию PCA3 и TMPRSS2-ERG в моче и ткани ПЖ. По результатам патоморфологического исследования каждая выборка разделялась на группы: РПЖ и доброкачественные изменения в ПЖ (ДГПЖ и хронический простатит). Экспрессия РСА3 в ткани и в моче у пациентов с РПЖ (Ме РСА3 в ткани 3,1 (1,2:4,9); Ме РСА3 в моче -0,04 (-0,6:2,1)) была выше, чем у пациентов с доброкачественными изменениями в ПЖ (Ме РСА3 в ткани 9,1 (6,9:10,4); Ме РСА3 в моче 4,4 (1,3:7,4)) (р

Еще

Диагностика рпж, молекулярно-генетические маркеры, рса3

Короткий адрес: https://sciup.org/142188021

IDR: 142188021

Список литературы PCA3 и TMPRSS2-ERG в диагностике РПЖ: первый опыт применения комбинации маркеров в России

  • Cancer Facts and Figures 2014. American Cancer Society, 2014. Р.19.
  • Schröder FH, Hugosson J, Roobol MJ,Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Paez A, Määttänen L, Bangma CH, Aus G, Carlsson S, Villers A, Rebillard X, van der Kwast T, Kujala PM, Blijenberg BG, Stenman U, Huber A, Taari K, Hakama M, Moss SM, de Koning HJ, Auvinen A. Prostate-Cancer Mortality at 11 Years of Follow-up.//N Engl J Med. 2012. Vol. 366. P. 981-990.
  • Schröder FH, Hugosson J, Carlsson S, Tammela T, Määttänen L, Auvinen A, Kwiatkowski M, Recker F, Roobol MJ. Screening for prostate cancer decreas-es the risk of developing metastatic disease: findings from the European Ran-domized Study of Screening for Prostate Cancer (ERSPC).//Eur Urol. 2012. Vol. 62. P. 745-752.
  • Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, Carroll P, Etzioni R. Overdiagnosis and overtreatment of prostate cancer. // Eur Urol. 2014. Vol. 65, N 6. P.1046-1055.
  • Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer.//JAMA.1995. Vol. 273, N 4. P. 289-294.
  • Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, Crowley JJ, Parnes HL, Coltman CA. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.//JAMA. 2005. Vol. 294, N 1. P. 66-70.
  • Ankerst DP, Thompson IM. Sensitivity and specificity of prostate-specific antigen for prostate cancer detection with high rates of biopsy verification.//Arch Ital Urol Androl.2006. Vol. 78, N 4. P. 125-129.
  • Wolf AM, Wender RC, Etzioni RB, Thompson IM, D'Amico AV, Volk RJ, Brooks DD, Dash C, Guessous I, Andrews K, DeSantis C, Smith R.A. American Cancer Society guideline for the early detection of prostate cancer: update 2010.//CA Cancer J Clin.2010. Vol. 60, N 2. P. 70-98.
  • Sershon PD, Barry MJ, Oesterling JE. Serum prostate-specific antigen discriminates weakly between men with benign prostatic hyperplasia and patients with organ-confined prostate cancer. // Eur Urol. 1994. Vol. 25. P. 281-287.
  • Chybowski FM, Bergstralh EJ, Oesterling JE. The effect of digital rectal examination on the serum prostate specific antigen concentration: results of a randomized study.//J Urol.1992. Vol. 148, N 1. P. 83-86.
  • Effect of digital rectal examination on serum prostate-specific antigen in a primary care setting. The Internal Medicine Clinic Research Consortium.//Arch Intern Med.1995. Vol. 155, N 4. P. 389-392.
  • Herschman JD, Smith DS, Catalona WJ. Effect of ejaculation on serum total and free prostate-specific antigen concentrations. // Urology. 1997. Vol. 50, N 2. P. 239-243.
  • Tchetgen MB, Song JT, Strawderman M, Jacobsen SJ, Oesterling JE. Ejaculation increases the serum prostate-specific antigen concentration. // Urology. 1996. Vol. 47, N 4. P. 511-516.
  • Tchetgen MB, Oesterling JE. The effect of prostatitis, urinary retention, ejaculation, and ambulation on the serum prostate-specific antigen concentration. // Urol Clin North Am. 1997. Vol. 24, N 2. P. 283-291.
  • Kawakami J, Siemens DR, Nickel JC. Prostatitis and prostate cancer: implications for prostate cancer screening. // Urology. 2004. Vol. 64, N 6. P. 1075-1080.
  • Simardi LH, Tobias-MacHado M, Kappaz GT, Goldenstein TP, Potts JM, Wroclawski ER. Influence of asymptomatic histologic prostatitis on serum prostate-specific antigen: a prospective study. // Urology. 2004. Vol. 64, N 6. P. 1098-1101.
  • Guess HA, Heyse JF, Gormley GJ. The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia. // Prostate. 1993. Vol. 22, N 1. P. 31-37.
  • Roehrborn CG, Marks LS, Fenter T, Freedman S, Tuttle J, Gittleman M, Mor-rill B, Wolford ET. Efficacy and safety of dutasteride in the four-year treat-ment of men with benign prostatic hyperplasia. // Urology. 2004. Vol. 63, N 4. P. 709-715.
  • Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Määttänen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A. Screening and prostate-cancer mortality in a randomized European study. // N Engl J Med. 2009. Vol. 360, N 13. P. 1320-1328.
  • Diagnosis and monitoring of prostate cancer: PROGENSA PCA3 assay and Prostate Health Index (PHI). National Institute for Health and Care Excellence, 2014. P. 39-41.
  • Stroumbakis N, Cookson MS, Reuter VE, Fair WR. Clinical significance of repeat sextant biopsies in prostate cancer patients.//Urology. 1997. Vol. 49, Suppl 3A. P113-118.
  • Ellis WJ, Brawer MK. Repeat prostate needle biopsy: who needs it?//J Urol. 1995. Vol. 153, N 5. P. 1496.
  • Adhyam M, Gupta AK. A Review on the clinical utility of PSA in cancer prostate. // Indian J Surg Oncol. 2012. Vol. 3, N 2. P. 120-129.
  • Louie KS, Seigneurin A, Cathcart P, Sasieni P. Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis. // Ann Oncol. 2015. Vol. 26, N 5. P. 848-864.
  • Salagierski M, Schalken JA. Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion. // J Urol. 2012. Vol. 187. P. 795-801.
  • Schilling DA, Hennenlotter J, von Weyhern CH, Kuehs U, Joerg T, Pelzer A, Stenzl A. Does the PCA3 score depend on tumor localization within the prostate? -A morphometric computer animated analysis.//J Urol. 2009. Vol. 181, Suppl. 4. P. 655.
  • Vlaeminck-Guillem V, Bandel M, Cottancin M, Rodriguez-Lafrasse C, Bohbot JM, Sednaoui P. Chronic prostatitis does not influence urinary PCA3 score//Prostate. 2012. Vol. 72, N 5. P. 549-554.
  • Warrick JI, Tomlins SA, Carskadon SL, Young AM, Siddiqui J, Wei JT, Chin-naiyan AM, Kunju LP, Palanisamy N. Evaluation of tissue PCA3 expression in prostate cancer by RNA in situ hybridization - a correlative study with urine PCA3 and TMPRSS2-ERG. // Mod Pathol. 2014. Vol. 27, N 4. P. 609-620.
  • Albino G, Capoluongo E, Rocchetti S, Palumbo S, Zuppi C, Cirillo-Marucco E. Evaluation of the diagnostic and predictive power of PCA3 in the prostate cancer. A different best cut-off in each different scenario. Preliminary results.//Arch Ital Urol Androl.2014. Vol. 86, N 4. P. 306-310.
  • Capoluongo E, Zambon CF, Basso D, Boccia S, Rocchetti S, Leoncini E, Palumbo S, Padoan A, Albino G, Todaro A, Prayer-Galetti T, Zattoni F, Zuppi C, Plebani M. PCA3 score of 20 could improve prostate cancer detection: results obtained on 734 Italian individuals. // Clin Chim Acta. 2014. Vol. 429. P. 46-50.
  • Gittelman MC, Hertzman B, Bailen J, Williams T, Koziol I, Henderson RJ, Efros M, Bidair M, Ward JF. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study. // J Urol. 2013. Vol. 190, N 1. P. 64-69.
  • Ochiai A, Okihara K, Kamoi K, Oikawa T, Shimazui T, Murayama S, Tomita K, Umekawa T, Uemura H, Miki T. Clinical utility of the prostate cancer gene 3 (PCA3) urine assay in Japanese men undergoing prostate biopsy.//BJU Int. 2013. Vol. 111, N 6. P. 928-933.
  • Stephan C, Jung K, Semjonow A, Schulze-Forster K, Cammann H, Hu X, Meyer HA, Bögemann M, Miller K, FriedersdorffF. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer. // Clin Chem. 2013. Vol. 59, N 1. P. 280-288.
  • Leyten GH, Hessels D, Jannink SA, Smit FP, de Jong H, Cornel EB, de Reijke TM, Vergunst H, Kil P, Knipscheer BC, van Oort IM, Mulders PF, Hulsber-genvan de Kaa CA, Schalken JA. Prospective multicentre evaluation of PCA3 and TM-PRSS2-ERG gene fusions as diagnostic and prognostic urinary bi-omarkers for prostate cancer. // Eur Urol. 2014. Vol. 65, N 3. P. 534-542.
  • Cornu JN, Cancel-Tassin G, Egrot C, Gaffory C, Haab F, Cussenot O. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer. //Prostate. 2013. Vol. 73, N 3. P. 242-249.
  • Perdonà S, Bruzzese D, Ferro M, Autorino R, Marino A, Mazzarella C, Perru-olo G, Longo M, Spinelli R, Di Lorenzo G, Oliva A, De Sio M, Damiano R, Altieri V, Terracciano D. Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy. // Prostate. 2013. Vol. 73, N 3. P. 227-235.
  • Augustin H, Mayrhofer K, Pummer K, Mannweiler S. Relationship between prostate cancer gene 3 (PCA3) and characteristics of tumor aggressiveness. // Prostate. 2013. Vol. 73, N 2. P. 203-210.
  • Ramos CG, Valdevenito R, Vergara I, Anabalon P, Sanchez C, Fulla J. PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience.//Urol Oncol. 2013. Vol. 31, N 8. P. 1522-1526.
  • Ferro M, Bruzzese D, Perdonà S, Mazzarella C, Marino A, Sorrentino A, Di Carlo A, Autorino R, Di Lorenzo G, Buonerba C, Altieri V, Mariano A, Macchia V, Terracciano D. Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers. //Clin Chim Acta. 2012. Vol. 413, N 15-16. P. 1274-1278.
  • Durand X, Xylinas E, Radulescu C, Haus-Cheymol R, Moutereau S, Ploussard G, Forgues A, Robert G, Vacherot F, Loric S, Allory Y, Ruffion A, de la Taille A. The value of urinary prostate cancer gene 3 (PCA3) scores in predicting pathological features at radical prostatectomy. // BJU Int. 2012. Vol. 110, N 1. P. 43-49.
  • Auprich M, Augustin H, Budäus L, Kluth L, Mannweiler S, Shariat SF, Fisch M, Graefen M, Pummer K, Chun FK. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, pros-tate-specific antigen velocity and urinary prostate cancer gene 3 in the first, se-cond and third repeat prostate biopsy. // BJU Int. 2012. Vol. 109, N 11. P. 1627-1635.
  • de la Taille A, Irani J, Graefen M, Chun F, de Reijke T, Kil P, Gontero P, Mottaz A, Haese A. Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions. // J Urol. 2011. Vol. 185, N 6. P. 2119-2125.
  • Durand X, Moutereau S, Xylinas E, de la Taille A. Progensa™ PCA3 test for prostate cancer. // Expert Rev Mol Diagn. 2011. Vol. 11, N 2. P. 137-144.
  • Nyberg M, Ulmert D, Lindgren A, Lindström U, Abrahamsson PA, Bjartell A. PCA3 as a diagnostic marker for prostate cancer: a validation study on a Swe-dish patient population. // Scand J Urol Nephrol. 2010. Vol. 44, N 6. P. 378-383.
  • Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, van Balken B. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. // Eur Urol. 2003. Vol. 44. P. 8-15.
  • Van Gils MP, Hessels D, Van Hooij O, Jannink SA, Peelen WP, Hanssen SL. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. // Clin Cancer Res. 2007. Vol. 13. P. 939-943.
  • Сидоренков А.В., Говоров А.В., Пушкарь Д.Ю., Павлов К.А., Шкопоров А.Н., Хохлова Е.В., Корчагина А.А., Григорьев М.Э., Чехонин В.П. Российская тест-система РСА3: первые результаты//Экспериментальная и клиническая урология. 2014. N 2. С. 44-49.
  • Ng CF, Yeung R, Chiu PK, Lam NY, Chow J, Chan B. The role of urine prostate cancer antigen 3 mRNA levels in the diagnosis of prostate cancer among Hong Kong Chinese patients. // Hong Kong Med J. 2012. Vol.18, N 6. P. 459-465.
  • Yong L, Xin G, Peng H, Chan M. Prostate cancer antigen 3 test for prostate biopsy decision: a systematic review and meta analysis.//Chin Med J (Engl). 2014. Vol. 127, N 9. P.1768-1774.
  • Сивков А.В., Ефремов Г.Д., Михайленко Д.С., Григорьева М.В. Комбинация маркеров РСА3 и TMPRSS2-ERG в ранней диагностике рака предстательной железы (обзор литературы).//Экспериментальная и клиническая урология. 2014. N 3. C. 20-26.
  • Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. // Science. 2005. Vol. 310. P. 644-648.
  • Attard G, Clark J, Ambroisine L, Fisher G, Kovacs G. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. // Oncogene. 2008. Vol. 27. P. 253-263.
  • Hermans KG, van Marion R, van Dekken H, Jenster G, van Weerden W M, Trapman J. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.// Cancer Res. 2006. Vol. 66. P. 10658-10663.
  • Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, Setlur S. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. // Cancer Res. 2006. Vol. 66. P. 8337-8341.
  • Iljin K, Wolf M, Edgren H, Gupta S, Kilpinen S, I.Skotheim R. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. // Cancer Res. 2006. Vol. 66, N 21. P. 10242-10246.
  • Wang J, Cai Y, Ren C, Ittmann M. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer.//Cancer Res. 2006. Vol. 66. P. 8347-8351.
  • Yoshimoto M, Joshua AM, Chilton-Macneill S, Bayani J, Selvarajah S, Evans AJ. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with re-arrangement.//Neoplasia. 2006. Vol. 8. P. 465-469.
  • Clark J, Merson S, Jhavar S, Flohr P, Edwards S, Foster CS. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. // Oncogene. 2007. Vol. 26. P. 2667-2673.
  • Hessels D, Smit FP, Verhaegh GW, Witjes JA, Cornel EB, Schalken JA. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. // Clinical Cancer Res. 2007. Vol. 13. P. 5103-5108.
  • Nguyen PN, Violette P, Chan S, Tanguay S, Kassouf W, Aprikian A, Chen JZ. A panel of TMPRSS2:ERG fusion transcript markers for urine-based prostate cancer detection with high specificity and sensitivity. // Eur Urol. 2011. Vol. 59, N 3. P.407-414.
  • Laxman B, Tomlins SA, Mehra R, Morris DS, Wang L, Helgeson BE, Shah RB, Rubinb MA, Wei JT, Chinnaiyan AM. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. // Neoplasia. 2006. Vol. 8, N 10. P. 885-888.
  • Bories PN, Younes P, Zerbib M, Denjean L, Popovici T, Cynober L, Delongchamps N.B. TMPRSS2-ERG fusion transcripts in matched urine and needle rinse material after biopsy for the detection of prostate cancer.//Clin Chem. 2013. Vol. 59.P. 245-251.
  • Tomlins SA, Aubin SM, Siddiqui J, Lonigro RJ, Sefton-Miller L, Miick S, Williamsen S, Hodge P, Meinke J, Blase A, Penabella Y, Day JR, Varambally R, Han B, Wood D, Wang L, Sanda MG, Rubin MA, Rhodes DR, Hollenbeck B, Sakamoto K, Silberstein JL, Fradet Y, Amberson JB, Meyers S, Palanisamy N, Rittenhouse H, Wei JT, Groskopf J, Chinnaiyan AM. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. // Sci Transl Med. 2011. Vol. 3, N 94. P. 72.
  • Salami SS, Schmidt F, Laxman B, Regan MM, Rickman DS, Scherr D, Bueti G, Siddiqui J, Tomlins SA, Wei JT, Chinnaiyan AM, Rubin MA, Sanda MG. Combining urinary detection of TMPRSS2: ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. // Urol Oncol. 2011. Vol. 31, N 5. P. 566-571.
  • Lin DW, Newcomb LF, Brown EC, Brooks JD, Carroll PR, Feng Z, Gleave ME, Lance RS, Sanda MG, Thompson IM, Wei JT, Nelson PS. Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the canary prostate active surveillance study. // Clin Cancer Res. 2013. Vol. 19. P. 2442-2450.
  • Laxman B, Morris DS, Yu J. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer.//Cancer Res. 2008 Vol. 68. P. 645.
  • Robert G, Jannink S, Smit F, Aalders T, Hessels D, Cremers R, Mulders PF, Schalken JA. Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis. // Prostate. 2012. Vol. 73, N 2. P. 113-120.
Еще
Статья научная
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp